Catalent Signs RL21 Anti-Cancer Development Deal with Pure MHC

Article

Catalent has signed a product development agreement with immunology company Pure MHC (major histocompatibility complex), which specializes in MHC-based diagnostics and therapeutics.

Catalent announced that it has signed a product development agreement with immunology company Pure MHC (major histocompatibility complex), which specializes in MHC-based diagnostics and therapeutics.

Under the terms of the agreement, Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody and engineer a cell line to express the antibody using Catalent’s GPEx technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A for the treatment of cancer. GPEx technology is used to generate mammalian cells with high yields and stability, helping to speed drugs to clinic.


Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets. Antibodies such as RL21A distinguish primary cancers from healthy tissue and, in animal models, have been shown to arrest tumor development.


Source: Catalent

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.